PEspeaks

Jan 18, 2017
Pharmaceutical Executive
Rethinking views on limited-efficacy drug approvals may be in order, says Casey McDonald.
Jan 17, 2017
The long-cherished dream of finding a European approach to assessing the value of new medicines seems to recede further with every step taken to pursue it, writes Reflector.
Jan 10, 2017
The Lancet's series of papers on moving from universal health care to "right care" for health offers a global and comprehensive perspective, writes Leela Barham. But what does "right care" mean for the industry?
Jan 09, 2017
By Pharmaceutical Executive Editors
Pharm Exec is back at the 2017 J.P. Morgan Healthcare Conference in San Francisco, CA.
Jan 03, 2017
For pharma companies, there continues to be a wide variety of tools to acquire revenues and pipeline drugs, but the valuations are challenging, writes Peter Young.
Dec 21, 2016
2016 has been the year of the unpredictable — and the uncertainties this has generated will multiply and dominate the agenda in Europe in 2017, writes Reflector.
Dec 12, 2016
Pharmaceutical Executive
Republican control of Washington promises overhaul of healthcare and medical product regulation.
Dec 09, 2016
Pharmaceutical Executive
Despite industry's success in translating discovery research into products with proven clinical value, it continues to struggle in positioning medical research to the public as a distinctive force for good, writes William Looney.
Nov 30, 2016
From Applied Clinical Trials
The FDA’s Dr. John Whyte offers his perspectives on patient centricity and the issues that FDA and industry are facing.
Nov 29, 2016
The European Medicine Association is determined keep open all options on the future of drug approvals in advance of a crucial meeting in December, writes Reflector.
native1_300x100
lorem ipsum